World Gin Day 2019: Cannabis with your Gin?
This is an older exclusive article for FinFeed subscribers which is now opened up. If you'd like to see new exclusive articles every week, please subscribe to our newsletter.
Saturday was World Gin Day — a global celebration of all things gin.
Always on the second Saturday in June, World Gin Day is now in its tenth year. The idea is simple and pretty straight forward (as explained by the organised Emma Stokes, aka Gin Monkey): “get people together all around the world with a legitimate excuse to drink some gin”.
But rather than going for the standard G&T, it might be time to live a little and try out some of the more interesting gin varieties...
In what might be peak gin culture, one local Melbourne business, The Cannabis Company, which sells a range of hemp-derived products for both humans and pets, is getting in on the action as the “first in the world to distil hemp gin using cannabis terpenes”.
The Cannabis Company sells three cannabis-infused gins: The Myrcene – the world's first cannabis-infused gin distilled with terpenes; Jilyngin Dreaming – a cannabis-terpene hemp gin distilled with native Australian botanicals; and High Seas – navy strength (116 proof) gin.
I asked Finfeed’s in-house gin connoisseur, Chris A, for his expert opinion. While he hasn’t yet tried it himself, his expectations are tempered: “I was talking to a bar tender the other night about it and he was saying it’s basically a gimmick. Hemp doesn’t have that much flavour in it to really make a difference. That being said I’d like to try it but won’t be rushing out to buy a bottle anytime soon.”
(He, for what it’s worth, personally likes dry gins – Never Never Juniper Freak, Prohibition Gin, Patient Wolf Melbourne Dry).
But maybe this focus on the taste is missing the point entirely.
The Cannabis Company claim when you ingest cannabis together with terpenes, you get a synergistic and uniquely positive effect. It says, “People are coming back to us with mad claims – it’s improved their sleep, it keeps them calm, it even cures the symptoms of their fibromyalgia.”
Here’s one such claim:
“Hi guys, I just wanted to write to you because my friends are all telling me that I’m mental. I don’t know if this is a placebo effect or what, but it seems that when I drink your gin either before or after smoking weed, I get about 30% more stoned!? Am I imagining this? I know you do the whole scientific thing so what’s the go?”
The go, according to the Cannabis Co., is that when the terpene myrcene is present in your bloodsteam and you ingest cannabis, it acts as an express receptor. You receive the cannabinoids from the cannabis faster, and it acts longer.
The terpene Myrcene is known as an anti-bacterial, anti-diabetic, anti-inflammatory, anti-insomniatic, anti-proliferative, antipsychotic, and anti-spasmodic. Cannabinoids have been demonstrated to absorb more efficiently into the blood brain barrier when terpenes are present, allowing them to bind to receptors in the endocannabinoid system.
So when the terpene myrcene is present in your bloodstream and you ingest cannabis, it acts as an express receptor. You receive the cannabinoids from the cannabis faster, and it acts longer.
So basically, it will help you get high (which, by the way, is not yet legal in Australia).
On the topic of cannabis, ASX-listed medicinal cannabis company Creso Pharma (ASX: CPH) delivered shareholders with some welcome news yesterday.
The company received a A$122 million takeover offer from Canadian cannabis company PharmaCielo Limited (TSXV:PCLO), the largest cannabis producer in Colombia.
This offer to $0.63 per share — a 50% premium to CPH’s Thursday closing price.
Cheers to that.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.